<li id="yesmc"><object id="yesmc"></object></li>
  • <dd id="yesmc"><s id="yesmc"></s></dd>
  • <menu id="yesmc"><noscript id="yesmc"></noscript></menu>
  • <center id="yesmc"><cite id="yesmc"></cite></center>
  • <dfn id="yesmc"><dl id="yesmc"></dl></dfn>
  • ×

    Company Profile


    Founded in 1985, Tonghua Dongbao Pharmaceutical Co., Ltd. has built a solid reputation as a pharmaceutical manufacturer that boasts strengths in the R&D, production, and marketing of pharmaceuticals, particularly Chinese patent medicines, chemical medicines, and biological products. Our most lauded products include Zhennaoning Capsules, Dongbao Gantai Tablets, Tangjierui Repaglinide Tablets, Tangjieen Engagliflozin Tablets, Gansulin? Recombinant Human Insulin, and Pingsulin? Insulin Glargine, and Ruisulin? Insulin Aspart, and Tongboli Liraglutide. Tonghua Dongbao was listed on the Shanghai Stock Exchange in August 1994.


    Over the years, we have maintained our philosophy of establishing a global brand through consistent innovation. Tonghua Dongbao developed the first Chinese made human insulin, with the trade name Gansulin, in 1998. Gansulin thus established China as the world’s third producer of recombinant human insulin following the United States and Denmark, and helped China overcome years of dependence on imports of the medicine. This achievement won the second prize of the National Science and Technology Progress Award and was listed in the "Top 10 Scientific Breakthroughs 1998". Tonghua Dongbao was also awarded many honorary titles such as National Technology Innovation Demonstration Enterprise and National High-tech Enterprise, and Dongbao? and Gansulin? were recognized as China’s well-known trademarks.


    In June 2008, Tonghua Dongbao successfully commercialized the research results to expand the annual production capacity of recombinant human insulin drug substances to 3,000 kg and became the first EU cGMP-certified biopharmaceutical manufacturer in China. Tonghua Dongbao began to build the third manufacturing plant of recombinant human insulin and the production lines of insulin glargine and insulin aspart in 2012 and 2014 respectively. We have an annual production capacity of over 300 million cartridges & vials now. In 2016, we started to invest in the construction of the Biopharmaceutical Industrial Park, which includes: Pharmaceutical Research Institute of Tonghua Dongbao and Quality Testing Center, production bases of insulin degludec, liraglutide drug substances and injection, wastewater treatment plant, acetonitrile recycling station, etc. Tonghua Dongbao Pharmaceutical Research Institute has begun operations since March 2021.


    Our insulin analog: insulin glargine, insulin aspart, insulin aspart mix 70/30 and mix 50/50 have been available on the market since February 2020, December 2021, and December 2022 respectively. GLP-1RA Liraglutide injection approved for marketing in December 2023. In addition, we have 4 oral anti-diabetic hypoglycemic drugs obtained the Pharmaceutical Product Registration Certificate issued by NMPA: sitagliptin phosphate tablets, sitagliptin phosphate/metformin hydrochloride tablets, repaglinide tablets, engagliflozin tablets. Besides, etoricoxib tablets received the notice of acceptance from the NMPA on the NDA application in September 2023.

    Today, Tonghua Dongbao provides the world with five novel drugs, including three for diabetes and two for gout. Among them, first subject enrolled in Phase I clinical trial on first Chinese-made dual-target inhibitor for gout (THDBH151 Tablets) in May 2023, novel URAT1 inhibitor for gout meets primary endpoint in phase II clinical trial in January 2024. In diabetes therapy area, first subject enrolled in Phase I clinical trial on GLP-1/GIP receptor agonist (THDBH120 Injections) and oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules) in December 2023.

    Tonghua Dongbao advances its international strategy continuously. Based upon domestic market, while further expanding overseas markets. Tonghua Dongbao has an international registration team and an overseas sales team for international business expansion. We have already established business contacts with key regional clients in Southeast Asia, the Middle East, East Asia, South America, and Africa, and have established strategic cooperation with multiple well-known domestic enterprises, to explore overseas market jointly. Besides, in early 2020, we started filing for the registration of insulin glargine and insulin lispro in the European Union and other developing countries.

    In the days to come, we will stay true to our philosophy of establishing a global brand through consistent innovation. We will enhance our capabilities in innovation-driven biopharmaceutical R&D and scale up the commercialization of research results to contribute toward achieving the goal of health for all.


    • 1985

      Year of funding

    • RMB30.75bn

      Realize operating income (2023)

    • 387+

      Number of R&D staff

    • 26+

      Categories of popular products

    Milestones

    2021

    • 5 March 2021

      Tonghua Dongbao and WuXi AppTec (Shanghai) signed the Memorandum of Understanding on Strategic Cooperation, specifying the intention of both parties to start extensive cooperation in the development of novel drugs for diabetes and other diseases, signaling its foray into the realm of novel drugs.


    • 8 March 2021

      Tonghua Dongbao Pharmaceutical Research Institute began operations.


    • 27 June 2021

      Tonghua Dongbao won the Best Public Service Award in the 10th Chinese Listed Companies Forum.


    2020

    • 27 January 2020

      Tonghua Dongbao donated RMB 1 million to the China Red Cross Foundation for the COVID-19 pandemic control in Wuhan.


    • 4 February 2020

      Tonghua Dongbao rolled out the first lot of Changsulin? insulin glargine injections, or the insulin analog.


    • 21 February 2020

      Tonghua Dongbao donated RMB 22 million worth of drugs and RMB 1 million in cash to the Tonghua Red Cross Society to support the COVID-19 pandemic control in Tonghua.



    • 14 September 2020

      Tonghua Dongbao received the notification of acceptance by the Center for Drug Evaluation of the NMPA on the application for the clinical trial of ultra-rapid-acting insulin lispro injections.


    • 14 October 2020

      Tonghua Dongbao ranked 14th in the Top 100 Pharmaceutical Enterprises 2019 issued by the Expert Committee of China Top 100 Pharmaceutical Industry.


    • 23 November 2020

      Tonghua Dongbao received NMPA approval for the clinical trial of ultra-rapid-acting insulin lispro injections.


    • 26 November 2020

      Tonghua Dongbao was recognized as an enterprise with outstanding contributions in the fight against the pandemic in Tonghua.


    2019

    • March 2019

      Mr. Li Yikui, the founder of Dongbao Group, resigned as chairman and exited the Board of Directors. Mr. Li Jiahong took over as the Chairman and General Manager of Dongbao Group, and Dr. Leng Chunsheng served as Chairman and General Manager of Tonghua Dongbao.


    • 6 December 2019

      Tonghua Dongbao received the registration approval for insulin glargine, or the insulin analog.

    2018

    • 26 April 2018

      Tonghua Dongbao and Adocia SAS signed the Agreement for Cooperation and Licensing of Ultra-rapid-acting Insulin and the Agreement for Cooperation and Licensing of BioChaperone Combo.


    • May 2018

      The insulin research team led by Dr. Leng Chunsheng was awarded the honorary title of Huang Danian Research Team in Jilin Province.

    2017

    • 20 October 2017

      The NMPA issued the approval for the clinical trial of insulin detemir drug substances and insulin detemir injection.


    • 9 November 2017

      Jilin Medical Products Administration issued the notification of acceptance of the application for the clinical trial of recombinant insulin lispro drug substances and recombinant insulin lispro injection.


    • 16 November 2017

      NMPA issued the notification of acceptance of the application for registration of liraglutide drug substances and liraglutide injection.


    • 16 November 2017

      Tonghua Dongbao received the notification of acceptance for the application for the phase III clinical trial of recombinant human insulin injection in the EU.


    • 25 November 2017

      Tonghua Dongbao was recognized as a national high-tech enterprise.

    2016

    • 16 March 2016

      Gansulin R is named as one of the Famous Brands in Jilin.


    • April 2016

      The Biopharmaceutical Industrial Park was settled in Tonghua Pharmaceutical Hi-tech Industrial Development Zone. The groundbreaking ceremony was held on July 16.


    • 7 June 2016

      The Adverse Drug Reaction Reporting and Monitoring Center (ADR Monitoring Center) was established.

    Culture

    企業(yè)文化(英文).jpg
    国产欧美视频一区二区不卡,女人午夜天堂在线播放,国产午夜亚洲精品不卡,亚洲最新网站在线 亚洲人成久久环射 国产精品激情欧美
    <li id="yesmc"><object id="yesmc"></object></li>
  • <dd id="yesmc"><s id="yesmc"></s></dd>
  • <menu id="yesmc"><noscript id="yesmc"></noscript></menu>
  • <center id="yesmc"><cite id="yesmc"></cite></center>
  • <dfn id="yesmc"><dl id="yesmc"></dl></dfn>